Substance / Medication

Glatiramer

Overview

Active Ingredient
glatiramer
RxNorm CUI
214582

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

59 trials linked to this intervention

59
Total Trials
13
Recruiting
25
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.
Kasindi Arielle, Fuchs Dieu-Trang, Koronyo Yosef et al. · Cells · 2022
PMID: 35563884Meta-AnalysisFull text (PMC)
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Signori Alessio, Gallo Fabio, Bovis Francesca et al. · Mult Scler Relat Disord · 2016
PMID: 27063624Meta-Analysis
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia Loredana, Di Pietrantonj Carlo, Rovaris Marco et al. · Cochrane Database Syst Rev · 2016
PMID: 27880972Meta-AnalysisFull text (PMC)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia Loredana, Di Pietrantonj Carlo, Rovaris Marco et al. · Cochrane Database Syst Rev · 2014
PMID: 25062935Meta-Analysis
Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
Qizilbash Nawab, Mendez Ignacio, Sanchez-de la Rosa Rainel · Clin Ther · 2012
PMID: 22284996Meta-Analysis
Glatiramer acetate for multiple sclerosis.
La Mantia Loredana, Munari Luca M, Lovati Roberta · Cochrane Database Syst Rev · 2010
PMID: 20464733Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Glatiramer (substance)
SNOMED CT
372535006
UMLS CUI
C0717787
RxNorm CUI
214582

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
59
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.